Published in Br J Cancer on September 05, 2005
Adaptive dose-finding studies: a review of model-guided phase I clinical trials. J Clin Oncol (2014) 1.33
Experimental designs for phase I and phase I/II dose-finding studies. Br J Cancer (2006) 1.31
Bridging Solutions in Dose Finding Problems. Stat Biopharm Res (2014) 0.99
New approaches to pharmacotherapy of tumors of the nervous system during childhood and adolescence. Pharmacol Ther (2009) 0.78
Innovations for phase I dose-finding designs in pediatric oncology clinical trials. Contemp Clin Trials (2016) 0.76
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Repair of O(6)-alkylguanine by alkyltransferases. Mutat Res (2000) 3.05
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer (1992) 2.91
Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol (2002) 2.40
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer (2003) 2.38
Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer (1993) 2.18
p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res (2001) 1.80
Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol (2002) 1.63
Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol (1995) 1.61
Continual reassessment method for ordered groups. Biometrics (2003) 1.60
Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res (1996) 1.47
Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res (1994) 1.37
Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res (2000) 1.35
Two-sample continual reassessment method. J Biopharm Stat (1999) 1.32
Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res (2002) 1.22
O6-alkylguanine-DNA alkyltransferase assay. Methods Mol Biol (2000) 1.20
Conduct of phase I trials in children with cancer. J Clin Oncol (1998) 1.16
Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol (2003) 1.11
Genomic instability and tolerance to alkylating agents. Cancer Surv (1996) 1.11
Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro. Br J Cancer (1996) 1.08
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. Ann Oncol (1999) 1.04
Modulation of mammalian O6-alkylguanine-DNA alkyltransferase in vivo by O6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea. Cancer Commun (1990) 1.03
Pharmacological strategies to increase the antitumor activity of methylating agents. Curr Med Chem (2002) 1.03
O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. Int J Cancer (2000) 1.03
Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group. J Clin Oncol (1998) 1.01
First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. J Clin Oncol (2004) 1.00
Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group. Br J Cancer (1998) 0.99
Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer (1994) 0.97
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clin Cancer Res (1999) 0.97
Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. J Neurooncol (2004) 0.96
Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukaemic patients. Ann Oncol (1995) 0.96
Attenuation of O(6)-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells. J Pharmacol Exp Ther (2000) 0.95
Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs. Int J Cancer (1996) 0.94
Another look at two phase I clinical trial designs. Stat Med (1999) 0.94
O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts. Int J Cancer (2000) 0.93
Role of wild-type p53 on the antineoplastic activity of temozolomide alone or combined with inhibitors of poly(ADP-ribose) polymerase. J Pharmacol Exp Ther (1998) 0.90
Metabolism of O6-benzylguanine, an inactivator of O6-alkylguanine-DNA alkyltransferase. Cancer Res (1994) 0.88
Enhancement of platinum-induced cytotoxicity by O6-benzylguanine. Mol Cancer Ther (2003) 0.86
Cisplatin increases sensitivity of human leukemic blasts to triazene compounds. J Chemother (1995) 0.84
Inactivation of O6-alkylguanine-DNA alkyltransferase in HeLa cells by cisplatin. Carcinogenesis (1989) 0.84
Commentary Stat Med (1999) 0.77
Mesoscale iron enrichment experiments 1993-2005: synthesis and future directions. Science (2007) 4.92
Small-bowel changes in dermatitis herpetiformis. Lancet (1966) 4.49
A mesoscale phytoplankton bloom in the polar Southern Ocean stimulated by iron fertilization. Nature (2000) 4.36
Sequence and expression of a membrane-associated C-type lectin that exhibits CD4-independent binding of human immunodeficiency virus envelope glycoprotein gp120. Proc Natl Acad Sci U S A (1992) 3.02
Neuroblastoma in Europe: differences in the pattern of disease in the UK. SENSE. Study group for the Evaluation of Neuroblastoma Screening in Europe. Lancet (1998) 2.77
Coeliac syndrome in dermatitis herpetiformis. Lancet (1968) 2.73
Detection of a novel human class II HLA antigen. Nature (1983) 2.61
Caspase activation during spontaneous and radiation-induced apoptosis in the murine intestine. J Pathol (2001) 2.53
Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: review of nine cases. Am J Med (1988) 2.19
Mechanisms of carcinogenesis induced by alkylating agents. Biochim Biophys Acta (1985) 2.13
Characterisation and nucleotide sequence of ogt, the O6-alkylguanine-DNA-alkyltransferase gene of E. coli. Nucleic Acids Res (1987) 2.07
Transition from maternal to embryonic control in early mammalian development: a comparison of several species. Mol Reprod Dev (1990) 2.07
Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. Lancet (1995) 2.06
Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res (2000) 2.05
Case report: a preterm infant with an extradural myxopapillary ependymoma component of a teratoma and high levels of alpha-fetoprotein. Pediatr Hematol Oncol (1999) 2.01
Differential expression of bcl-2 in intestinal epithelia. Correlation with attenuation of apoptosis in colonic crypts and the incidence of colonic neoplasia. J Cell Sci (1995) 2.01
Use of hypertonic saline in the treatment of severe refractory posttraumatic intracranial hypertension in pediatric traumatic brain injury. Crit Care Med (2000) 1.98
Enzymatic release of 7-methylguanine from methylated DNA by rodent liver extracts. Proc Natl Acad Sci U S A (1981) 1.87
Cloning of the E. coli O6-methylguanine and methylphosphotriester methyltransferase gene using a functional DNA repair assay. Nucleic Acids Res (1985) 1.87
Carcinogenicity of N-methyl-N-nitrosourea: possible role of excision repair of O6-methylguanine from DNA. J Natl Cancer Inst (1974) 1.76
The effect of starvation and refeeding on cell population kinetics in the rat small bowel mucosa. J Anat (1975) 1.73
Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Proc Natl Acad Sci U S A (1997) 1.73
Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology Study. J Clin Oncol (2005) 1.70
hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene (1997) 1.67
Small intestine in psoriasis. Br Med J (1967) 1.66
Primary biliary cirrhosis--a revised clinical spectrum. Lancet (1981) 1.64
Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol (2002) 1.63
Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer (1993) 1.60
N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique. J Clin Oncol (1997) 1.59
Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors. Am J Hum Genet (1999) 1.57
Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood (1992) 1.55
Comprehensive screening for constitutional RB1 mutations by DHPLC and QMPSF. Hum Mutat (2004) 1.52
Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev (2006) 1.51
Neurofibromatosis and early onset of cancers in hMLH1-deficient children. Cancer Res (1999) 1.50
High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol (1991) 1.49
High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study. Bone Marrow Transplant (1992) 1.49
Medicare payment policy and recombinant erythropoietin prescribing for dialysis patients. Am J Kidney Dis (1993) 1.48
Biological implications of the instability of the N-glycosidic bone of 3-methyldeoxyadenosine in DNA. Biochim Biophys Acta (1973) 1.48
Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology. J Clin Oncol (2001) 1.48
Portal vein thrombosis during antineoplastic chemotherapy in children: report of five cases and review of the literature. Eur J Cancer (2004) 1.47
Estimating average regression effect under non-proportional hazards. Biostatistics (2000) 1.47
Liver damage after paracetamol overdose. Comparison of liver-function tests, fasting serum bile acids, and liver histology. Lancet (1975) 1.46
Dural sinus thrombosis in children with cancer. Med Pediatr Oncol (1997) 1.45
A radiation-controlled molecular switch for use in gene therapy of cancer. Gene Ther (2000) 1.45
Targeted deletion of alkylpurine-DNA-N-glycosylase in mice eliminates repair of 1,N6-ethenoadenine and hypoxanthine but not of 3,N4-ethenocytosine or 8-oxoguanine. Proc Natl Acad Sci U S A (1997) 1.44
Spectrum of germline mutations in the RB1 gene: a study of 232 patients with hereditary and non hereditary retinoblastoma. Hum Mol Genet (1995) 1.44
Meeting the challenges facing research ethics committees: some practical suggestions. BMJ (1998) 1.43
Neglected vaginal ring pessary. J Obstet Gynaecol (2006) 1.42
Dw/LD-related molecular polymorphism of DR4 beta-chains. J Exp Med (1983) 1.42
European collaboration in trials of new agents for children with cancer. Eur J Cancer (2004) 1.42
Effects of colony stimulating factor-1 on human extravillous trophoblast growth and invasion. J Endocrinol (1998) 1.41
Pancreatic trauma in Scottish children. J R Coll Surg Edinb (2000) 1.40
Has in-vitro fertilization made salpingostomy obsolete? Br J Obstet Gynaecol (1990) 1.40
[Severe hyperlactacidemia in 2 children treated for malignant tumors. Role of vitamin B1]. Arch Fr Pediatr (1991) 1.39
Apoptosis and gastrointestinal disease. J Pediatr Gastroenterol Nutr (2000) 1.39
Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification. Br J Cancer (2007) 1.39
Assessment of the acoustic properties of common tissue-mimicking test phantoms. Ultrasound Med Biol (2003) 1.37
Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. Ann Oncol (2003) 1.36
Methylated purines in the deoxyribonucleic acid of various Syrian-golden-hamster tissues after administration of a hepatocarcinogenic dose of dimethylnitrosamine. Biochem J (1976) 1.35
Clinical utility of a monoclonal direct fluorescent reagent specific for Legionella pneumophila: comparative study with other reagents. J Clin Microbiol (1985) 1.35
O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. Cancer Res (1991) 1.34
Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine. Proc Natl Acad Sci U S A (1999) 1.33
Initial chemotherapy in gliomatosis cerebri. Neurology (2004) 1.33
Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis? Hepatology (1987) 1.32
Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood. Int J Cancer (1998) 1.32
A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer (2011) 1.31
Reduction of the toxicity and mutagenicity of alkylating agents in mammalian cells harboring the Escherichia coli alkyltransferase gene. Proc Natl Acad Sci U S A (1986) 1.31
Molecular cloning and expression of a cDNA encoding the rabbit ileal villus cell basolateral membrane Na+/H+ exchanger. EMBO J (1991) 1.31
The International Neuroblastoma Risk Groups (INRG): a preliminary report. Eur J Cancer (1997) 1.30
Impact of targeting deviations on outcome in medulloblastoma: study of the French Society of Pediatric Oncology (SFOP). Int J Radiat Oncol Biol Phys (1999) 1.30
Repair of O-alkylpyrimidines in mammalian cells: a present consensus. Proc Natl Acad Sci U S A (1988) 1.30
Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma. Ann Neurol (1999) 1.29
Treatment of stage 4s neuroblastoma--report of 10 years' experience of the French Society of Paediatric Oncology (SFOP). Br J Cancer (2003) 1.29
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer (1998) 1.29
Incidence of small-intestinal mucosal abnormalities and of clinical coeliac disease in the relatives of children with coeliac disease. Gut (1971) 1.28
Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial. Lancet (2004) 1.27
Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant (1988) 1.27
Pathological features of the colonic tumours induced in rats by the administration of 1,2-dimethylhydrazine. Virchows Arch B Cell Pathol (1978) 1.26
Acute renal disease, as defined by the RIFLE criteria, post-liver transplantation. Am J Transplant (2006) 1.25
Histological, cytological and immunological analyses are complementary for the detection of neuroblastoma cells in bone marrow. Br J Cancer (1986) 1.25
Chemical carcinogenesis in the nervous system. Preferential accumulation of O6-methylguanine in rat brain deoxyribonucleic acid during repetitive administration of N-methyl-N-nitrosourea. Biochem J (1975) 1.24
Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells. Nucleic Acids Res (2001) 1.24
Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant (1999) 1.23